Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

538 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis.
Kato K, Fujii N, Makita S, Goto H, Kanda J, Shimada K, Akashi K, Izutsu K, Teshima T, Fukuda N, Sumitani T, Nakamura S, Sumi H, Shimizu S, Kakurai Y, Yoshikawa K, Tobinai K, Usui N, Hatake K. Kato K, et al. Among authors: kanda j. Int J Hematol. 2023 Mar;117(3):409-420. doi: 10.1007/s12185-022-03494-7. Epub 2022 Nov 18. Int J Hematol. 2023. PMID: 36399286 Clinical Trial.
Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system.
Tauchi T, Kizaki M, Okamoto S, Tanaka H, Tanimoto M, Inokuchi K, Murayama T, Saburi Y, Hino M, Tsudo M, Shimomura T, Isobe Y, Oshimi K, Dan K, Ohyashiki K, Ikeda Y; TARGET Investigators. Tauchi T, et al. Leuk Res. 2011 May;35(5):585-90. doi: 10.1016/j.leukres.2010.10.027. Epub 2010 Dec 10. Leuk Res. 2011. PMID: 21145591
Graft-versus-host disease and survival after cord blood transplantation for acute leukemia: a comparison of Japanese versus White populations.
Kuwatsuka Y, Atsuta Y, Horowitz MM, Inagaki J, Kanda J, Kato K, Koh K, Zhang MJ, Eapen M; Center for International Blood and Marrow Transplant Research (CIBMTR), and Donor/Source and GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). Kuwatsuka Y, et al. Among authors: kanda j. Biol Blood Marrow Transplant. 2014 May;20(5):662-7. doi: 10.1016/j.bbmt.2014.01.020. Epub 2014 Feb 10. Biol Blood Marrow Transplant. 2014. PMID: 24525277 Free PMC article.
Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups.
Inamoto Y, Kimura F, Kanda J, Sugita J, Ikegame K, Nakasone H, Nannya Y, Uchida N, Fukuda T, Yoshioka K, Ozawa Y, Kawano I, Atsuta Y, Kato K, Ichinohe T, Inoue M, Teshima T; JSHCT GVHD Working Group. Inamoto Y, et al. Among authors: kanda j. Haematologica. 2016 Dec;101(12):1592-1602. doi: 10.3324/haematol.2016.149427. Epub 2016 Aug 4. Haematologica. 2016. PMID: 27662017 Free PMC article.
Deferasirox for the treatment of iron overload after allogeneic hematopoietic cell transplantation: multicenter phase I study (KSGCT1302).
Tachibana T, Kanda J, Machida S, Saito T, Tanaka M, Najima Y, Koyama S, Miyazaki T, Yamamoto E, Takeuchi M, Morita S, Kanda Y, Kanamori H, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Tachibana T, et al. Among authors: kanda j, kanda y. Int J Hematol. 2018 May;107(5):578-585. doi: 10.1007/s12185-017-2396-9. Epub 2018 Jan 5. Int J Hematol. 2018. PMID: 29305770 Clinical Trial.
Impact of graft-versus-host disease on relapse and survival after allogeneic stem cell transplantation for pediatric leukemia.
Kato M, Kurata M, Kanda J, Kato K, Tomizawa D, Kudo K, Yoshida N, Watanabe K, Shimada H, Inagaki J, Koh K, Goto H, Kato K, Cho Y, Yuza Y, Ogawa A, Okada K, Inoue M, Hashii Y, Teshima T, Murata M, Atsuta Y. Kato M, et al. Among authors: kanda j. Bone Marrow Transplant. 2019 Jan;54(1):68-75. doi: 10.1038/s41409-018-0221-6. Epub 2018 May 24. Bone Marrow Transplant. 2019. PMID: 29795428 Clinical Trial.
Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma.
Yamasaki S, Chihara D, Kim SW, Kawata T, Mizuta S, Ago H, Chou T, Yamane T, Uchiyama H, Oyake T, Miura K, Saito B, Taji H, Nakamae H, Miyamoto T, Fukuda T, Kanda J, Atsuta Y, Suzuki R. Yamasaki S, et al. Among authors: kanda j. Int J Hematol. 2019 Feb;109(2):175-186. doi: 10.1007/s12185-018-2560-x. Epub 2018 Nov 14. Int J Hematol. 2019. PMID: 30430419
Cytomegalovirus reactivation is associated with increased mortality more than 100 days after allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma.
Sawayama Y, Itonaga H, Fukushima T, Nakano N, Fujiwara H, Utsunomiya A, Fukuda T, Miyamoto T, Eto T, Miyashita K, Nakamae H, Ogata M, Yamanoha A, Miyazaki Y, Kanda J, Atsuta Y, Kato K; ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation. Sawayama Y, et al. Among authors: kanda j. Am J Hematol. 2019 May;94(5):E143-E146. doi: 10.1002/ajh.25438. Epub 2019 Mar 6. Am J Hematol. 2019. PMID: 30773707 Free article. No abstract available.
Effect of graft-versus-host disease on outcomes after pediatric single cord blood transplantation.
Kanda J, Umeda K, Kato K, Murata M, Sugita J, Adachi S, Koh K, Noguchi M, Goto H, Yoshida N, Sato M, Koga Y, Hori T, Cho Y, Ogawa A, Inoue M, Hashii Y, Atsuta Y, Teshima T; JSHCT GVHD Working Group. Kanda J, et al. Bone Marrow Transplant. 2020 Jul;55(7):1430-1437. doi: 10.1038/s41409-020-0853-1. Epub 2020 Mar 11. Bone Marrow Transplant. 2020. PMID: 32161321
538 results